Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis

• Published in: Turkish journal of haematology 2010-10, Vol.27 (3), p.162-167
• Main Authors: Osman Yokuş, Özlem Şahin Balçık, Murat Albayrak, Funda Ceran, Simten Dağdaş, Mesude Yılmaz, Gülsüm Özet
• Format: Article
• Language: English
• Subjects: cerebral venous thrombosis; thrombophilia; thrombophilic defects
• ISSN: 1308-5263
• DOI: 10.5152/tjh.2010.23

OBJECTIVE: The increased risk for thrombosis is known as hypercoagulability or thrombophilia. In our study, we aimed to compare the frequency of the identified defects for thrombophilia in patients with central venous thrombosis and under the age of 50 years, with the findings in the current literature. METHODS: Forty-three patients (16-50 years old) were retrospectively evaluated. Thrombophilia investigation included determinations of protein C, protein S, antithrombin, and activated protein C resistance, factor V Leiden (FVL), prothrombin 20210A (PT 20210) and methylene tetrahydrofolate reductase (MTHFR) C677T mutations, antiphospholipid antibodies (APA), factor VIII levels, and homocysteine levels. RESULTS: We detected a single thrombophilic defect in 67.4%, two defects in 27.9% and three defects in 4.7% of our patients. The most common thrombophilic defect was mutation in the MTHFR gene (41.8%), and this was followed by the FVL mutation (34.9%). CONCLUSION: Since the prevalence of individual thrombophilic defects varies in each population, ethnic group and geographical location, screening for thrombophilic defects in patients presenting with cerebral venous thrombosis should primarily investigate the most frequent thrombophilia risk factors.